fda ban compounded tirzepatide Lilly seeks to intervene in lawsuit The U.S. Food and Drug

Phase 2 trial data (Jastreboff et al., NEJM, 2023) demonstrated substantial weight reduction participants lost a mean of approximately 24% of body weight over 48 weeks at the highest doses alongside improvements in cardiometabolic markers

2 : 333337 Reynolds CF, Frank E, Kupfer DJ, Thase ME, Perel JM, Mazumdar S et al

Excess weight around the neck creates fatty deposits that narrow airways, while abdominal weight compresses lungs and decreases airflow 35

NICE has approved specific GLP-1 receptor agonists (semaglutide [Wegovy] in TA875 and liraglutide [Saxenda] in TA664) for weight management in eligible patients, subject to NHS local prescribing criteria